News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

International Therapeutics, Inc. Announces ProxiQuant License To Rosetta Inpharmatics, Inc. (MRK) To Quantify Gene Expression Interfering Molecules -- RNAi



10/19/2005 5:09:13 PM

International Therapeutics, Inc. announced today that it has agreed to provide Rosetta Inpharmatics LLC (Seattle, WA) a world-wide nonexclusive license to its proprietary ProxiQuant(TM) technology for research and development applications.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES